Clinical Trials
34 trialsNCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT03084536 2024-12-24
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
Phase 2 Completed
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT02484664 2022-01-20
COLA
Brigham and Women's Hospital
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00061893 2019-02-15
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT00088972 2018-08-10
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
Phase 2 Terminated
NCT01220973 2018-06-08
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT01729923 2018-01-16
ADAPT
University of Washington
Phase 2 Terminated
NCT00081263 2017-09-15
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
GOG Foundation
Phase 2 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT00499655 2017-03-29
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00520845 2017-03-20
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00099047 2016-12-30
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00291694 2016-11-07
Protocol for Women at Increased Risk of Developing Breast Cancer
University of Kansas Medical Center
Phase 2 Completed
NCT00198081 2016-02-29
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Indiana University
Phase 2 Terminated
NCT00250835 2015-09-01
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00201773 2015-06-30
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00068770 2015-03-18
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00357500 2014-10-01
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01678313 2014-07-15
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
Buddhist Tzu Chi General Hospital
Phase 2 Completed
NCT00698204 2014-06-05
Cox-2 Inhibition in Radiation-induced Oral Mucositis
UConn Health
Phase 2 Completed
NCT00466505 2012-12-19
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00527982 2012-12-06
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00592319 2012-08-31
Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Boston University
Phase 2 Terminated
NCT01158534 2012-08-07
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00504660 2012-01-11
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038103 2010-02-25
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
Pfizer
Phase 2 Completed